Skip to main content
Top
Published in: Current Hematologic Malignancy Reports 6/2016

01-12-2016 | Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Authors: Naveen Pemmaraju, Vikas Gupta, Michael A. Thompson, Andrew A. Lane

Published in: Current Hematologic Malignancy Reports | Issue 6/2016

Login to get access

Abstract

The incorporation of Internet resources and the use of social media among patients, clinicians, advocates, and researchers in the field of hematology and oncology are growing in importance. Utilization of online information sharing is rising, especially among those involved in rare blood cancer fields, which have generally featured a paucity of reliable, updated information. In particular, blastic plasmacytoid dendritic cell neoplasm (BPDCN), an uncommon, but highly aggressive hematologic malignancy, is one example of a cancer with limited information readily available to the general public. The infrequent incidence of BPDCN, the challenges in recognizing the disease and making a clinico-pathologic diagnosis, and the lack of standard therapies are some of the reasons accounting for the dearth of expert opinion, scientific publications and discussion, and accessibility of online information for patients. This article highlights social media and Internet sources available for patients and other healthcare stakeholders in the field of BPDCN and discusses our efforts to increase awareness and propagation of BPDCN electronic resources, including the founding of an online Twitter community, #BPDCN.
Literature
1.
go back to reference Andrew P, Vickers MM, O'Connor S, Valdes M, Tang PA. Media reporting of practice-changing clinical trials in oncology: a North American perspective. Oncologist. 2016;21(3):269–78.CrossRefPubMed Andrew P, Vickers MM, O'Connor S, Valdes M, Tang PA. Media reporting of practice-changing clinical trials in oncology: a North American perspective. Oncologist. 2016;21(3):269–78.CrossRefPubMed
2.
go back to reference Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social media and the practicing hematologist: twitter 101 for the busy healthcare provider. Curr Hematol Malig Rep. 2015;10(4):405–12.CrossRefPubMedPubMedCentral Thompson MA, Majhail NS, Wood WA, Perales MA, Chaboissier M. Social media and the practicing hematologist: twitter 101 for the busy healthcare provider. Curr Hematol Malig Rep. 2015;10(4):405–12.CrossRefPubMedPubMedCentral
3.
go back to reference Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26(9):782, 784–5, 791. Thompson MA, Younes A, Miller RS. Using social media in oncology for education and patient engagement. Oncology (Williston Park). 2012;26(9):782, 784–5, 791.
4.
go back to reference Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (mpn)-focus on twitter and the development of a disease-specific community: #mpnsm. Curr Hematol Malig Rep. 2015. Pemmaraju N, Gupta V, Mesa R, Thompson MA. Social media and myeloproliferative neoplasms (mpn)-focus on twitter and the development of a disease-specific community: #mpnsm. Curr Hematol Malig Rep. 2015.
6.
go back to reference Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:6520. Katz MS, Utengen A, Anderson PF, Thompson MA, Fisch M, Johnston C. Disease-specific hashtags for online communication about cancer care. J Clin Oncol. 2015;33:6520.
7.
go back to reference Attai DJ, Sedrak MS, Katz MS, et al. Social media in cancer care: highlights, challenges & opportunities. Future Oncol. 2016. Attai DJ, Sedrak MS, Katz MS, et al. Social media in cancer care: highlights, challenges & opportunities. Future Oncol. 2016.
8.
go back to reference Xu S, Markson C, Costello KL, Xing CY, Demissie K, Llanos AA. Leveraging social media to promote public health knowledge: example of cancer awareness via twitter. JMIR Public Health Surveillance. 2016;2(1):e17.CrossRefPubMedPubMedCentral Xu S, Markson C, Costello KL, Xing CY, Demissie K, Llanos AA. Leveraging social media to promote public health knowledge: example of cancer awareness via twitter. JMIR Public Health Surveillance. 2016;2(1):e17.CrossRefPubMedPubMedCentral
9.
go back to reference Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17(7):e188.CrossRefPubMedPubMedCentral Attai DJ, Cowher MS, Al-Hamadani M, Schoger JM, Staley AC, Landercasper J. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res. 2015;17(7):e188.CrossRefPubMedPubMedCentral
12.
go back to reference Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (AYA) patient with cancer. Curr Hematol Malig Rep. 2016. Perales MA, Drake EK, Pemmaraju N, Wood WA. Social media and the adolescent and young adult (AYA) patient with cancer. Curr Hematol Malig Rep. 2016.
13.
go back to reference Borgmann H, Woelm JH, Merseburger A, et al. Qualitative twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. Can Urol Assoc J. 2016;10(1–2):39–44.CrossRefPubMedPubMedCentral Borgmann H, Woelm JH, Merseburger A, et al. Qualitative twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference. Can Urol Assoc J. 2016;10(1–2):39–44.CrossRefPubMedPubMedCentral
14.
go back to reference Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urol Oncol. 2016. Borgmann H, Loeb S, Salem J, et al. Activity, content, contributors, and influencers of the twitter discussion on urologic oncology. Urol Oncol. 2016.
15.
go back to reference Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.CrossRefPubMed
16.
go back to reference Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055–61.CrossRefPubMed Alayed K, Patel KP, Konoplev S, et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013;88(12):1055–61.CrossRefPubMed
17.
go back to reference Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–46.CrossRefPubMedPubMedCentral Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239–46.CrossRefPubMedPubMedCentral
18.
go back to reference Pemmaraju N ea. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): male predominance, propensity for extra-medullary involvement, and poor outcomes. ASCO Annual Meeting. 2014. Pemmaraju N ea. Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): male predominance, propensity for extra-medullary involvement, and poor outcomes. ASCO Annual Meeting. 2014.
19.
go back to reference Laribi K, Denizon N, Besancon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357–67. Laribi K, Denizon N, Besancon A, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357–67.
20.
go back to reference Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–81.PubMedPubMedCentral Martin-Martin L, Almeida J, Pomares H, et al. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016;7(9):10174–81.PubMedPubMedCentral
21.
go back to reference Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and hypercvad therapy. Am J Hematol. 2016;91(3):283–6.CrossRefPubMed Deotare U, Yee KW, Le LW, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: 10-color flow cytometry diagnosis and hypercvad therapy. Am J Hematol. 2016;91(3):283–6.CrossRefPubMed
22.
go back to reference Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14(4):220–2.PubMed Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm. Clin Adv Hematol Oncol. 2016;14(4):220–2.PubMed
23.
go back to reference Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559–62.CrossRefPubMed Aoki T, Suzuki R, Kuwatsuka Y, et al. Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood. 2015;125(23):3559–62.CrossRefPubMed
24.
go back to reference Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006–12.CrossRefPubMed Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2013;19(7):1006–12.CrossRefPubMed
25.
26.
go back to reference Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84.CrossRefPubMed Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84.CrossRefPubMed
27.
go back to reference Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.CrossRefPubMedPubMedCentral Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014;124(3):385–92.CrossRefPubMedPubMedCentral
28.
go back to reference LA Pemmaraju N, Sweet KL, Stein A, Sumithira V, Blum WG. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing. J Clin Oncol. 2016;34:7006. LA Pemmaraju N, Sweet KL, Stein A, Sumithira V, Blum WG. Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing. J Clin Oncol. 2016;34:7006.
29.
go back to reference Wells DM, Lehavot K, Isaac ML. Sounding off on social media: the ethics of patient storytelling in the modern era. Acad Med. 2015;90(8):1015–9.CrossRefPubMed Wells DM, Lehavot K, Isaac ML. Sounding off on social media: the ethics of patient storytelling in the modern era. Acad Med. 2015;90(8):1015–9.CrossRefPubMed
30.
go back to reference Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–46.CrossRefPubMed Reimer P, Rudiger T, Kraemer D, et al. What is CD4+CD56+ malignancy and how should it be treated? Bone Marrow Transplant. 2003;32(7):637–46.CrossRefPubMed
31.
go back to reference Dimov V, Eidelman F. Utilizing social networks, blogging and youtube in allergy and immunology practices. Expert Rev Clin Immunol. 2015;11(10):1065–8.CrossRefPubMed Dimov V, Eidelman F. Utilizing social networks, blogging and youtube in allergy and immunology practices. Expert Rev Clin Immunol. 2015;11(10):1065–8.CrossRefPubMed
32.
go back to reference Grajales 3rd FJ, Sheps S, Ho K, Novak-Lauscher H, Eysenbach G. Social media: a review and tutorial of applications in medicine and health care. J Med Internet Res. 2014;16(2):e13.CrossRefPubMed Grajales 3rd FJ, Sheps S, Ho K, Novak-Lauscher H, Eysenbach G. Social media: a review and tutorial of applications in medicine and health care. J Med Internet Res. 2014;16(2):e13.CrossRefPubMed
33.
go back to reference Lewis MA, Dicker AP. Social media and oncology: the past, present, and future of electronic communication between physician and patient. Semin Oncol. 2015;42(5):764–71.CrossRefPubMedPubMedCentral Lewis MA, Dicker AP. Social media and oncology: the past, present, and future of electronic communication between physician and patient. Semin Oncol. 2015;42(5):764–71.CrossRefPubMedPubMedCentral
35.
go back to reference Sedrak MS, Cohen RB, Merchant RM, Schapira MM. Cancer communication in the social media age. JAMA Oncol. 2016;2(6):822–3.CrossRefPubMed Sedrak MS, Cohen RB, Merchant RM, Schapira MM. Cancer communication in the social media age. JAMA Oncol. 2016;2(6):822–3.CrossRefPubMed
Metadata
Title
Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Authors
Naveen Pemmaraju
Vikas Gupta
Michael A. Thompson
Andrew A. Lane
Publication date
01-12-2016
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2016
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-016-0340-3

Other articles of this Issue 6/2016

Current Hematologic Malignancy Reports 6/2016 Go to the issue

T-CELL AND OTHER LYMPHOPROLIFERATIVE MALIGNANCIES (P PORCU, SECTION EDITOR)

Enteropathy-Associated T-Cell Lymphoma

Myelodysplastic Syndromes (D Steensma, Section Editor)

Improving Prognostic Modeling in Myelodysplastic Syndromes

Acute Myeloid Leukemias (H Erba, Section Editor)

Definition of Unfit for Standard Acute Myeloid Leukemia Therapy

T-Cell and Other Lymphoproliferative Malignancies (P Porcu, Section Editor)

Sézary Syndrome: Clinical and Biological Aspects

Myelodysplastic Syndromes (D Steensma, Section Editor)

Assessing Quality of Care for the Myelodysplastic Syndromes